Gilead Sciences, Inc. (GILD) stock
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 12/30104% above fair value
$168.98−1.28 (-0.75%)
Close on Nov 18, 2026Market cap $209.59BP/E –Yield 1.87%
Gilead Sciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Gilead Sciences's operating income for the twelve months ending Sep 30, 2026 was -$2.36B, down 122.5% year over year. For fiscal 2025 it was $10.02B, up 503.0% from the year before. Over ten years it grew -7.6% a year on average. The highest annual figure on record is $22.19B in fiscal 2015.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.02B | +503.0% |
| FY2024 | Dec 31, 2024 | $1.66B | -78.1% |
| FY2023 | Dec 31, 2023 | $7.61B | +3.8% |
| FY2022 | Dec 31, 2022 | $7.33B | -26.1% |
| FY2021 | Dec 31, 2021 | $9.92B | +143.6% |
| FY2020 | Dec 31, 2020 | $4.07B | -5.0% |
| FY2019 | Dec 31, 2019 | $4.29B | -47.7% |
| FY2018 | Dec 31, 2018 | $8.20B | -41.9% |
| FY2017 | Dec 31, 2017 | $14.12B | -19.9% |
| FY2016 | Dec 31, 2016 | $17.63B | -20.5% |
| FY2015 | Dec 31, 2015 | $22.19B | +45.4% |
| FY2014 | Dec 31, 2014 | $15.27B | +237.4% |
| FY2013 | Dec 31, 2013 | $4.52B | +12.8% |
| FY2012 | Dec 31, 2012 | $4.01B | +5.8% |
| FY2011 | Dec 31, 2011 | $3.79B | -4.4% |
| FY2010 | Dec 31, 2010 | $3.96B | +12.3% |
| FY2009 | Dec 31, 2009 | $3.53B | +31.8% |
| FY2008 | Dec 31, 2008 | $2.68B | +23.7% |
| FY2007 | Dec 31, 2007 | $2.16B | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $3.46B | +4.1% |
| Q2 FY2026 | Jun 30, 2026 | -$10.39B | -520.1% |
| Q1 FY2026 | Mar 31, 2026 | $2.59B | +15.6% |
| Q4 FY2025 | Dec 31, 2025 | $1.98B | -19.1% |
| Q3 FY2025 | Sep 30, 2025 | $3.33B | +274.7% |
| Q2 FY2025 | Jun 30, 2025 | $2.47B | -6.4% |
| Q1 FY2025 | Mar 31, 2025 | $2.24B | – |
| Q4 FY2024 | Dec 31, 2024 | $2.45B | +52.1% |
| Q3 FY2024 | Sep 30, 2024 | $888.00M | -66.1% |
| Q2 FY2024 | Jun 30, 2024 | $2.64B | +58.8% |
| Q1 FY2024 | Mar 31, 2024 | -$4.32B | -353.5% |
| Q4 FY2023 | Dec 31, 2023 | $1.61B | -28.9% |
| Q3 FY2023 | Sep 30, 2023 | $2.62B | -7.5% |
| Q2 FY2023 | Jun 30, 2023 | $1.67B | -17.9% |
| Q1 FY2023 | Mar 31, 2023 | $1.71B | +765.5% |
| Q4 FY2022 | Dec 31, 2022 | $2.27B | +141.2% |
| Q3 FY2022 | Sep 30, 2022 | $2.84B | -26.2% |
| Q2 FY2022 | Jun 30, 2022 | $2.03B | -9.7% |
| Q1 FY2022 | Mar 31, 2022 | $197.00M | -93.2% |
| Q4 FY2021 | Dec 31, 2021 | $940.00M | -64.5% |
| Q3 FY2021 | Sep 30, 2021 | $3.84B | +92.0% |
| Q2 FY2021 | Jun 30, 2021 | $2.25B | – |
| Q1 FY2021 | Mar 31, 2021 | $2.89B | +20.3% |
| Q4 FY2020 | Dec 31, 2020 | $2.65B | +142.5% |
| Q3 FY2020 | Sep 30, 2020 | $2.00B | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.98B | -222.8% |
| Q1 FY2020 | Mar 31, 2020 | $2.40B | +7.4% |
| Q4 FY2019 | Dec 31, 2019 | $1.09B | -4.5% |
| Q3 FY2019 | Sep 30, 2019 | -$1.47B | -156.2% |
| Q2 FY2019 | Jun 30, 2019 | $2.43B | +6.6% |
| Q1 FY2019 | Mar 31, 2019 | $2.24B | +3.9% |
| Q4 FY2018 | Dec 31, 2018 | $1.14B | -50.1% |
| Q3 FY2018 | Sep 30, 2018 | $2.62B | -31.2% |
| Q2 FY2018 | Jun 30, 2018 | $2.28B | -46.4% |
| Q1 FY2018 | Mar 31, 2018 | $2.15B | -42.8% |
| Q4 FY2017 | Dec 31, 2017 | $2.29B | -43.4% |
| Q3 FY2017 | Sep 30, 2017 | $3.81B | – |
| Q2 FY2017 | Jun 30, 2017 | $4.25B | – |
| Q1 FY2017 | Mar 31, 2017 | $3.77B | – |
| Q4 FY2016 | Dec 31, 2016 | $4.05B | – |
See a number that looks wrong?